TABLE 1.
Pharmacological effects of SS.
| System | Effect | Mechanism | Extracts or compounds | Models | In vitro/vivo | Treatment | References |
|---|---|---|---|---|---|---|---|
| Respiratory | Airway allergy reduction | Reduce TGF-β expression, MAPK phosphorylation, MMP9 and MMP2 protease activity | SS patch | Guinea pig asthma model | In vivo | 0.0625–0.5 mg ml−1 | Li (2017) |
| Downregulation of TGF-β1/Smad 3 pathway | SS patch | BALB/c Chronic asthma mice model | In vivo | 0.5 g | Liu et al. (2017) | ||
| Relaxes airway smooth muscle, increases lung and airway volume | Sinapine | Guinea pig asthma model | In vivo | 7.4–74 mg kg−1 | Wang et al. (2011) | ||
| Cough suppressant inhibition | Inhibition of the receptors in the cough reflex arc or the vagus nerve of the afferent cough impulses | 4-Hydroxybenzyl cyanide | Cough model | In vivo | 0.031 g kg−1 | Yu (2005) | |
| Digestive | Liver protection | Inhibition of BRD4 expression | Sinapic acid | C57BL/6 mice, AML-12 cells | In vivo, In vitro | 20 mg kg−1, 20 μM | Chu et al. (2021) |
| Inhibition of liver steatosis | Sinapine | C57BL/6 mice | In vivo | 500 mg kg−1 | Li et al. (2019) | ||
| NF-κB inhibits Nrf2/HO-1-mediated activation of antioxidant enzymes and apoptosis inhibition | Sinapic acid | Hepatotoxicity model | In vivo | 20, 40 mg kg−1 | Ahmad et al. (2021) | ||
| Reduced expression of TGF-β1, Smad4, p-Smad 2/3/Smad 2/3, p-NF-κB-p65/NF-κB-p65, IL-1β, IL-6 and p-AKT/AKT | SS extract | Hepatic fibrosis model | In vivo | 0.5, 1.0, and 2.0 g kg−1 | Cao et al. (2018) | ||
| Anti- adipocyte browning | Stimulation of mitochondrial biogenesis through AMPK, p38 MAPK and CREB pathways leads to white adipocyte browning | Sinapic acid | 3T3-L1 cells | In vitro | 1–20 μM | Bae and Kim (2020) | |
| Nervous | Protective neurological activity | Activation of BDNF/TrkB/ERK signaling pathway | Sinapic acid | PC12 cells | In vitro | 50–100 μM | Xue et al. (2021) |
| Enhance cell viability and inhibit oxidative stress and endoplasmic reticulum stress | Sinapic acid | SH-SY5Y cells | In vitro | 50–800 μM | Tungalag and Yang (2021) | ||
| Promotes CREB mRNA transcription | Sinapic acid | PC12 cells | In vitro | 100 μM | Xue et al. (2022) | ||
| Cardiovascular | Anti-hypertension | Inhibition of TNF-α production | Sinapine thiocyanate | Insulin resistance model | In vivo | 10, 30, and 90 mg kg−1 d−1 | Huang et al. (2018) |
| Inhibition of NLRP3 inflammatory vesicle activation | Sinapine thiocyanate | Spontaneously hypertensive rats, HUVECs | In vivo, In vitro | 8.54 mg kg−1, 50 mg L−1 | Liu et al. (2020) | ||
| Cardioprotective activity | Reduce oxidative stress and Ca+, anti-cardiac mitochondrial damage | Sinapic acid | Myocardial infarction rats | In vivo | 12 mg kg−1 | Stanely Mainzen Prince et al. (2020) | |
| Immunity | Anti-inflammatory effect | Inhibition of NLRP3 inflammatory vesicle activation | Sinapic acid | Bone marrow-derived macrophages | In vitro | 100–200 μM | Lee et al. (2021) |
| Increase the mRNA expression levels of ZO-1, Occludin, Claudin-1 and decrease the mRNA expression levels of TLR4, NF-kB, MLCK, IL-8, IL-1β | Sinapic acid | Caco-2 cells | In vitro | 5, 10, 15 μM | Zhang et al. (2019) | ||
| Reproductive | Anti-testicular damage activity | Reduce MDA, PC and NO levels and increase SOD and GSH- Px activity | Sinapic acid | Testicular torsion rat model | In vivo | 10, 20 mg kg−1 | Unsal et al. (2021) |
| Anti-prostatic hyperplasia activity | Reduce foreskin gland wet weight and serum acid phosphatase activity | Sinapine, β-sitosterol and sinalbin | Prostate hyperplasia model | In vivo | 8, 16 mg kg−1 | Wu et al. (2003a); Wu et al. (2003b) | |
| Tumors | Anti-cancer activity | Increase intracellular ferrous iron, lipid peroxidation and reactive oxygen species in non-small cell lung cancer cells; downregulation of SLC7A11 | Sinapine | NSCLC cells, bronchial epithelial cells | In vitro | 0–20 μM | Shao et al. (2022) |
| Inhibition of anti-apoptotic factor Bcl-2, promotion of pro-apoptotic factor Bax expression | Sinapine | H22 cells | In vitro | LC50 = 53.97 μg L−1 | Nan (2010) | ||
| Reduce protein expression of PTGS1, PTGS2, Bcl-2, MMP-2 and MMP-9 and increase protein expression of Bax in hepatoma cells SMMC-7721 | Sinapine thiocyanate | SMMC-7721 cells | In vitro | 0–100 μM | Chen et al. (2020) | ||
| Reduce the expression of p-AKT (S473), β-catenin, N-cadherin, Vimentin and PCNA in skin squamous carcinoma A431 and Colo-16 cells; increase the expression of E-cadherin | Sinapine thiocyanate | A431 cells, Colo-16 cells | In vitro | 20 μM | Su et al. (2021) | ||
| Inhibition of p-glycoprotein expression | Sinapine | Caco-2 cells | In vitro | 0–200 μM | Guo et al. (2014) | ||
| Other | Hypoglycemic effect | Inhibition of TNF-α production | Sinapine thiocyanate | Insulin resistance model | In vivo | 10, 30, and 90 mg kg−1 d−1 | Huang et al. (2018) |
| Kidney protective effect | Upregulation of PPAR-γ expression | Sinapic acid | Rat nephrotoxic model | In vivo | 20, 40 mg kg−1 | Singh et al. (2020) | |
| Anti-oxidant effect | Scavenging superoxide anion free radicals | Sinapine thiocyanate | Superoxide radicals | In vitro | IC50 = 0.135 mM | Li et al. (2012) | |
| Scavenging DPPH activity, scavenging hydrogen peroxide radicals and scavenging NO radicals | Sinapic acid | Human skin fibroblasts | In vitro | IC50 = 32.1 μM | Cos et al. (2002) |